{"transactions":[{"id":896446,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":6000,"derivative":{"exercise_price":10.84,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":896445,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":18000,"price":82.42,"value":1483560.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $81.47 to $83.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":896444,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T23:12:56.000Z","date":"2026-02-17","kind":"exercise","planned":false,"acquired":true,"shares":18000,"price":10.84,"value":195120.0,"ownership":{"direct":true},"balance_after":25825,"source":{"system":"sec-edgar","filing":"0001104659-26-017176","document":"tm266755-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926017176/tm266755-1_4seq1.xml","form_type":"4"}},{"id":946153,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:40:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":3762,"derivative":{"exercise_price":87.18,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":3762},"source":{"system":"sec-edgar","filing":"0001104659-26-001476","document":"tm262304-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001476/tm262304-5_4seq1.xml","form_type":"4"}},{"id":946152,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T00:40:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-001476","document":"tm262304-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001476/tm262304-5_4seq1.xml","form_type":"4"}},{"id":1310232,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T23:09:35.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":6584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":6584,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":6584},"source":{"system":"sec-edgar","filing":"0001104659-25-001432","document":"tm252003-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001432/tm252003-6_4seq1.xml","form_type":"4"}},{"id":1310231,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T23:09:35.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":5130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":5130,"source":{"system":"sec-edgar","filing":"0001104659-25-001432","document":"tm252003-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001432/tm252003-6_4seq1.xml","form_type":"4"}},{"id":1687506,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:14:20.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":25700,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":25700},"source":{"system":"sec-edgar","filing":"0001104659-24-001494","document":"tm241954-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001494/tm241954-6_4seq1.xml","form_type":"4"}},{"id":2052266,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T01:10:19.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments following the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-004737","document":"tm233829-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004737/tm233829-9_4seq1.xml","form_type":"4"}},{"id":2253126,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T20:01:44.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date."}],"balance_after":20000,"derivative":{"exercise_price":8.31,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-065862","document":"tm2214526-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922065862/tm2214526-5_4seq1.xml","form_type":"4"}},{"id":2406021,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2022-02-09T17:54:16.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":931228,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":931228},"source":{"system":"sec-edgar","filing":"0001209191-22-008160","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1475714/000120919122008160/doc4.xml","form_type":"4"}},{"id":2406020,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2022-02-09T17:54:16.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":1163886,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1163886},"source":{"system":"sec-edgar","filing":"0001209191-22-008160","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1475714/000120919122008160/doc4.xml","form_type":"4"}},{"id":2406019,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-09T17:54:16.000Z","date":"2022-02-08","kind":"exercise","acquired":true,"shares":2095114,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series B-1 Preferred Stock, par value $0.001 per share, and Series B-2 Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series B-1 Preferred Stock and Series B-2 Preferred Stock into Common Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares directly held by Quan Venture Fund II, L.P. The general partner of Quan Capital is Quan Venture Partners II, L.L.C. The Reporting Person, a member of the Issuer's board of directors, is a venture partner at Quan Venture Partners II, L.L.C. and, therefore, may be deemed to have a pecuniary interest over these shares. The Reporting Person disclaims beneficial ownership of the shares held of record by Quan Venture Fund II, L.P. except to the extent of his pecuniary interest therein."}],"balance_after":2095114,"source":{"system":"sec-edgar","filing":"0001209191-22-008160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1475714/000120919122008160/doc4.xml","form_type":"4"}},{"id":2691050,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T23:06:54.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":18000,"derivative":{"exercise_price":35.23,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121036680/doc4.xml","form_type":"4"}},{"id":2714319,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T21:39:26.000Z","date":"2021-05-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 11, 2021 until the option is fully vested on May 11, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":11.4,"expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-032406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000120919121032406/doc4.xml","form_type":"4"}},{"id":3130440,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T22:21:04.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":15000,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-033032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919120033032/doc4.xml","form_type":"4"}},{"id":3157930,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-07T20:28:48.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":12.84,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-027694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000120919120027694/doc4.xml","form_type":"4"}},{"id":3393587,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-15T20:44:18.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":22000,"derivative":{"exercise_price":2.82,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-19-025571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000089924319025571/doc4.xml","form_type":"4"}},{"id":3423461,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-04T13:20:35.000Z","date":"2019-09-01","kind":"tax_withholding","acquired":false,"shares":7024,"price":5.43,"value":38140.32,"ownership":{"direct":true},"balance_after":455336,"source":{"system":"sec-edgar","filing":"0001209191-19-048076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119048076/doc4.xml","form_type":"4"}},{"id":3492937,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-12T18:28:49.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the \"Company\"), subject to the reporting person's continued service to the Company through such vest date."}],"balance_after":15000,"derivative":{"exercise_price":6.09,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-036513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119036513/doc4.xml","form_type":"4"}},{"id":3493948,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T22:31:43.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-036211","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119036211/doc4.xml","form_type":"4"}},{"id":3626586,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-02-28T18:15:47.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":6400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment is being filed to reflect the grant to the reporting person of (i) 1,000 shares of restricted common stock of the Company and (ii) 6,400 options to purchase shares of common stock of the Company, each of which was inadvertently omitted from the reporting person's original Form 4 filed with the Securities and Exchange Commission (the \"SEC\") on February 27, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date."}],"balance_after":6400,"derivative":{"exercise_price":11.97,"expiration_date":"2029-02-24","underlying":"Common Stock","underlying_shares":6400},"source":{"system":"sec-edgar","filing":"0001209191-19-014685","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119014685/doc4a.xml","form_type":"4/A","original_submission_date":"2019-02-27"}},{"id":3626585,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-28T18:15:47.000Z","date":"2019-02-25","kind":"grant","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 25, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the \"Company\") through each such date."},{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment is being filed to reflect the grant to the reporting person of (i) 1,000 shares of restricted common stock of the Company and (ii) 6,400 options to purchase shares of common stock of the Company, each of which was inadvertently omitted from the reporting person's original Form 4 filed with the Securities and Exchange Commission (the \"SEC\") on February 27, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the holdings of the reporting person as of the date of the original Form 4 filed with the SEC on February 27, 2019, taking into account the transaction set forth in such original Form 4 and the transaction set forth in this amendment."}],"balance_after":462360,"source":{"system":"sec-edgar","filing":"0001209191-19-014685","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119014685/doc4a.xml","form_type":"4/A","original_submission_date":"2019-02-27"}},{"id":3629341,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-27T19:49:33.000Z","date":"2019-02-26","kind":"tax_withholding","acquired":false,"shares":926,"price":11.95,"value":11065.7,"ownership":{"direct":true},"balance_after":461360,"source":{"system":"sec-edgar","filing":"0001209191-19-014250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119014250/doc4.xml","form_type":"4"}},{"id":3670532,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-07T17:18:05.000Z","date":"2019-02-05","kind":"tax_withholding","acquired":false,"shares":3144,"price":11.43,"value":35935.92,"ownership":{"direct":true},"balance_after":462286,"source":{"system":"sec-edgar","filing":"0001209191-19-008141","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919119008141/doc4.xml","form_type":"4"}},{"id":3767199,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-11-13T20:32:39.000Z","date":"2018-11-05","kind":"exercise","acquired":false,"shares":91217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.56,"expiration_date":"2019-04-15","underlying":"Common Stock","underlying_shares":91217},"source":{"system":"sec-edgar","filing":"0001209191-18-058417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118058417/doc4.xml","form_type":"4"}},{"id":3767198,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-11-13T20:32:39.000Z","date":"2018-11-05","kind":"exercise","acquired":true,"shares":91217,"price":4.56,"value":415949.52,"ownership":{"direct":true},"balance_after":465430,"source":{"system":"sec-edgar","filing":"0001209191-18-058417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118058417/doc4.xml","form_type":"4"}},{"id":3825625,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-09-05T13:00:47.000Z","date":"2018-09-01","kind":"tax_withholding","acquired":false,"shares":7024,"price":14,"value":98336.0,"ownership":{"direct":true},"balance_after":374213,"source":{"system":"sec-edgar","filing":"0001209191-18-049446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118049446/doc4.xml","form_type":"4"}},{"id":3896618,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-12T22:55:13.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-037318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118037318/doc4.xml","form_type":"4"}},{"id":4027569,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-02-28T19:26:35.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month following February 26, 2018, provided the reporting person provides services the Company through each such date."}],"balance_after":30000,"derivative":{"exercise_price":18.69,"expiration_date":"2028-02-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-014712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118014712/doc4.xml","form_type":"4"}},{"id":4027568,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-28T19:26:35.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 26, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the \"Company\") through each such date."}],"balance_after":381237,"source":{"system":"sec-edgar","filing":"0001209191-18-014712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118014712/doc4.xml","form_type":"4"}},{"id":4063098,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-13T11:46:34.000Z","date":"2016-09-01","kind":"gift","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to reflect that a gift of 22,416 shares of common stock was inadvertently disclosed in the original Form 4 filed with the Securities and Exchange Commission (the \"SEC\") on February 9, 2017.  This gift was already reported in a Form 4 filed with the SEC on September 1, 2016 and as such, the original Form 4 filed on February 9, 2017 should not have included a line item for this gift. This amendment cannot be filed without a completed line item, and as such, this amendment shows that no shares were gifted."}],"balance_after":428827,"source":{"system":"sec-edgar","filing":"0001209191-18-009449","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118009449/doc4a.xml","form_type":"4/A","original_submission_date":"2017-02-09"}},{"id":4063097,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-13T11:36:09.000Z","date":"2016-09-01","kind":"gift","acquired":false,"shares":22416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment reflects that the reporting person's gift of 22,416 shares of common stock reported in the original Form 4 filed with the Securities and Exchange Commission on September 1, 2016 was not a market transaction and as such, no price is reported in this amendment. The reporting person did not receive any value for the gifted shares."}],"balance_after":409299,"source":{"system":"sec-edgar","filing":"0001209191-18-009446","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118009446/doc4a.xml","form_type":"4/A","original_submission_date":"2016-09-01"}},{"id":4063096,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-13T11:36:09.000Z","date":"2016-09-01","kind":"tax_withholding","acquired":false,"shares":32613,"price":44.74,"value":1459105.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to reflect the correct disposition of shares of common stock by the reporting person in satisfaction of a tax liability on September 1, 2016.  The original Form 4 filed with the Securities and Exchange Commission on September 1, 2016 inadvertently included a disposal of 7,613 shares of common stock rather than 32,613 shares of common stock, as shown in this amendment."}],"balance_after":431715,"source":{"system":"sec-edgar","filing":"0001209191-18-009446","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118009446/doc4a.xml","form_type":"4/A","original_submission_date":"2016-09-01"}},{"id":4072281,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2018-02-07T14:19:39.000Z","date":"2018-02-05","kind":"tax_withholding","acquired":false,"shares":3137,"price":18.42,"value":57783.54,"ownership":{"direct":true},"balance_after":376237,"source":{"system":"sec-edgar","filing":"0001209191-18-008075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919118008075/doc4.xml","form_type":"4"}},{"id":4216233,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2017-09-06T20:00:13.000Z","date":"2017-09-01","kind":"tax_withholding","acquired":false,"shares":7827,"price":34.34,"value":268779.18,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 600 shares acquired on November 15, 2016 and 431 shares acquired on May 15, 2017 pursuant to Five Prime Therapeutics, Inc.'s 2013 Employee Stock Purchase Plan."}],"balance_after":381958,"source":{"system":"sec-edgar","filing":"0001209191-17-051801","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117051801/doc4.xml","form_type":"4"}},{"id":4280557,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-15T23:36:42.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of June 15, 2017."}],"balance_after":24000,"derivative":{"exercise_price":10.84,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-17-040261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117040261/doc4.xml","form_type":"4"}},{"id":4404927,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2017-03-03T13:38:32.000Z","date":"2017-03-01","kind":"tax_withholding","acquired":false,"shares":34532,"price":44.77,"value":1545997.64,"ownership":{"direct":true},"balance_after":388754,"source":{"system":"sec-edgar","filing":"0001209191-17-017144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117017144/doc4.xml","form_type":"4"}},{"id":4459719,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-09T19:36:36.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":101250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date."}],"balance_after":101250,"derivative":{"exercise_price":45.38,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":101250},"source":{"system":"sec-edgar","filing":"0001209191-17-009300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117009300/doc4.xml","form_type":"4"}},{"id":4459718,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2017-02-09T19:36:36.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":16875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date."}],"balance_after":423286,"source":{"system":"sec-edgar","filing":"0001209191-17-009300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117009300/doc4.xml","form_type":"4"}},{"id":4459717,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2017-02-09T19:36:36.000Z","date":"2016-09-01","kind":"gift","acquired":false,"shares":22416,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":406411,"source":{"system":"sec-edgar","filing":"0001209191-17-009300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117009300/doc4.xml","form_type":"4"}},{"id":4498916,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2017-01-05T14:32:55.000Z","date":"2017-01-03","kind":"tax_withholding","acquired":false,"shares":5065,"price":48.6,"value":246159.0,"ownership":{"direct":true},"balance_after":428827,"source":{"system":"sec-edgar","filing":"0001209191-17-001849","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919117001849/doc4.xml","form_type":"4"}},{"id":4512575,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":false,"shares":29816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and immediately exercisable."}],"balance_after":31159,"derivative":{"exercise_price":5.54,"expiration_date":"2022-07-15","underlying":"Common Stock","underlying_shares":29816},"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512574,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":false,"shares":10,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and immediately exercisable."}],"balance_after":16349,"derivative":{"exercise_price":8.49,"expiration_date":"2021-10-19","underlying":"Common Stock","underlying_shares":10},"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512573,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":false,"shares":19,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and immediately exercisable."}],"balance_after":14438,"derivative":{"exercise_price":6.89,"expiration_date":"2020-07-28","underlying":"Common Stock","underlying_shares":19},"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512572,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Employee Stock Option (right to buy)","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":false,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and immediately exercisable."}],"balance_after":91217,"derivative":{"exercise_price":4.56,"expiration_date":"2019-04-15","underlying":"Common Stock","underlying_shares":155},"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512571,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"sale","acquired":false,"shares":300,"price":51.02,"value":15306.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive."}],"balance_after":433892,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512570,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"sale","acquired":false,"shares":29700,"price":50.49,"value":1499553.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4."}],"balance_after":434192,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512569,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":true,"shares":29816,"price":5.54,"value":165180.64,"ownership":{"direct":true},"balance_after":463892,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512568,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":true,"shares":10,"price":8.49,"value":84.9,"ownership":{"direct":true},"balance_after":434076,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512567,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":true,"shares":19,"price":6.89,"value":130.91,"ownership":{"direct":true},"balance_after":434066,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4512566,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-12-23T17:11:16.000Z","date":"2016-12-23","kind":"exercise","acquired":true,"shares":155,"price":4.56,"value":706.8,"ownership":{"direct":true},"balance_after":434047,"source":{"system":"sec-edgar","filing":"0001209191-16-156690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116156690/doc4.xml","form_type":"4"}},{"id":4602763,"issuer":{"id":16595,"kind":"organization","name":"FIVE PRIME THERAPEUTICS, INC.","symbol":"FPRX"},"owners":[{"id":65875,"kind":"person","name":"Williams Lewis T","position":1,"cik":"0001475714","reported_name":"Williams Lewis T","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Chairman"}}],"security":"Common Stock","published_at":"2016-09-15T19:09:05.000Z","date":"2016-09-14","kind":"gift","acquired":false,"shares":407,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":433892,"source":{"system":"sec-edgar","filing":"0001209191-16-141666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175505/000120919116141666/doc4.xml","form_type":"4"}}]}